New pill may help prevent lymphoma relapse after chemo

NCT ID NCT07300514

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated May 14, 2026 · Updated 18 times

Summary

This study tests whether the drug golidocitinib can help keep peripheral T-cell lymphoma (a type of blood cancer) from returning in patients who have already responded to initial chemotherapy. About 136 adults who are not eligible for or decline a stem cell transplant will receive either golidocitinib or a placebo pill every other day for up to 2 years. The goal is to see if the drug extends the time before the cancer progresses or comes back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, 200032, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) MAINTENANCE TREATMENT OF PERIPHERAL T-CELL LYMPHOMA PERIPHERAL T-CELL LYMPHOMA (PTCL NOS) T-FOLLICULAR HELPER PHENOTYPE PERIPHERAL T-CELL LYMPHOMA